Literature DB >> 7196685

Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study.

B J Maron, D D Savage, J K Wolfson, S E Epstein.   

Abstract

The prevalence and prognostic significance of ventricular arrhythmias identified on 24 hour ambulatory electrocardiographic monitoring was prospectively assessed in 99 patients with hypertrophic cardiomyopathy. In the absence of antiarrhythmic therapy, high grade ventricular arrhythmias (grade 3 and above) were common; that is they were identified in 66 percent of the patients, including 19 percent with episodes of asymptomatic ventricular tachycardia. Clinical outcome was assessed 3 years after the initial 24 hour ambulatory electrocardiogram. Of the 84 patients who did not undergo ventricular septal myotomy-myectomy, 6 died suddenly or experienced cardiac arrest, 1 died of progressive congestive heart failure and the other 77 have survived without a cardiac catastrophe. The prevalence rate of sudden death or cardiac arrest during the follow-up period was the same (3 percent) in patients with high grade arrhythmias other than ventricular tachycardia (1 of 37) as in those with no or low grade arrhythmias (1 of 29). However, the occurrence of a sudden cardiac catastrophe was significantly more common in patients with asymptomatic ventricular tachycardia of brief duration on 24 hour electrocardiography (4 [24 percent] of 17) than in patients without ventricular tachycardia (2 [3 percent] of 66) (p less than 0.02). In summary, (1) high grade ventricular arrhythmias are commonly found on continuous 24 hour electrocardiography monitoring in patients with hypertrophic cardiomyopathy; and (2) although sudden death is relatively uncommon in patients with high grade ventricular arrhythmias other than ventricular tachycardia (annual mortality rate 1 percent), the finding of ventricular tachycardia on 24 hour electrocardiography identifies a subgroup of patients at high risk for sudden death (annual mortality rate 8.6 percent). Although no conclusions can be drawn regarding the impact of therapy, our findings suggest that 24 hour electrocardiographic monitoring should be performed in patients with hypertrophic cardiomyopathy and that it may be reasonable to initiate antiarrhythmic therapy if ventricular tachycardia is identified.

Entities:  

Mesh:

Year:  1981        PMID: 7196685     DOI: 10.1016/0002-9149(81)90604-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  53 in total

Review 1.  Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death.

Authors:  William J McKenna; Elijah R Behr
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

2.  Symptomatic Ventricular Tachycardia.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-08

Review 3.  Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy.

Authors:  Michael P Frenneaux
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

Review 4.  Electrocardiographic predictors of arrhythmic death.

Authors:  Michael G McLaughlin; Peter J Zimetbaum
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-10       Impact factor: 1.468

Review 5.  Management of hypertrophic cardiomyopathy in children.

Authors:  Hubert Seggewiss; Angelos Rigopoulos
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 6.  [Long term electrocardiography (Holter monitoring)].

Authors:  Axel Brandes; Klaus-Peter Bethge
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2008-10-25

Review 7.  Molecular basis of hypertrophic and dilated cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  Tex Heart Inst J       Date:  1994

Review 8.  Potential mechanisms of improvement after various treatments for hypertrophic obstructive cardiomyopathy.

Authors:  R D Leachman
Journal:  Tex Heart Inst J       Date:  1995

9.  Cardiac dysrhythmias in children with idiopathic dilated or hypertrophic cardiomyopathy.

Authors:  G Müller; H E Ulmer; K J Hagel; D Wolf
Journal:  Pediatr Cardiol       Date:  1995 Mar-Apr       Impact factor: 1.655

10.  Prognosis of hypertrophic cardiomyopathy: assessment by 123I-BMIPP (beta-methyl-p-(123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography.

Authors:  T Nishimura; S Nagata; T Uehara; T Morozumi; Y Ishida; T Nakata; O Iimura; C Kurata; Y Wakabayashi; H Sugihara; K Otsuki; T Wada; Y Koga
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.